Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01416376
First received: July 28, 2011
Last updated: February 16, 2012
Last verified: February 2012
  Purpose

SRT2379 is a potent small molecule activator of SIRT1 that has been found to inhibit systemic inflammation induced by intravenous injection of lipopolysaccharide (LPS) in mice. The objective of this study is to determine the effect of a single administration of SRT2379, at multiple-dose levels, on the inflammatory response to low dose endotoxin.


Condition Intervention Phase
Sepsis
Drug: SRT2379
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Official Title: A Double Blind, Placebo Controlled, Phase I Dose-ranging Study to Evaluate the Activity of SRT2379 on Endotoxin Induced Inflammatory Response in Healthy Male Subjects

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Clinical signs and symptoms of inflammation will be used as a measure of the effect of multiple-dose levels of SRT2379 on the inflammatory response in normal healthy male subjects exposed to low-dose endotoxin (LPS). [ Time Frame: 12 days ] [ Designated as safety issue: No ]
  • Laboratory parameters of inflammation will be used as a measure of the effect of multiple-dose levels of SRT2379 on the inflammatory response in normal healthy male subjects exposed to low-dose endotoxin (LPS). [ Time Frame: 12 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Plasma levels of SRT2379 will be measured to assess the pharmacokinetics of SRT2379 in healthy male subjects exposed to low-dose endotoxin (LPS). [ Time Frame: 2 days ] [ Designated as safety issue: No ]
  • Number of participants with adverse events and incidence of adverse events will be used as a measure of safety and tolerability of multiple-dose levels of SRT2379 in healthy male subjects exposed to low-dose endotoxin (LPS). [ Time Frame: 34 days ] [ Designated as safety issue: No ]

Enrollment: 39
Study Start Date: August 2011
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 50mg SRT2379
Single oral administration of 50mg SRT2379
Drug: SRT2379
SRT2379 is supplied as hard gelatin capsules containing either 25mg or 250mg free-base equivalent of SRT23790 drug substance as its succinate salt.
Drug: Placebo
For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.
Active Comparator: 250mg SRT2379
Single oral administration of 250mg SRT2379
Drug: SRT2379
SRT2379 is supplied as hard gelatin capsules containing either 25mg or 250mg free-base equivalent of SRT23790 drug substance as its succinate salt.
Drug: Placebo
For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.
Active Comparator: 1000mg SRT2379
Single oral administration of 1000mg SRT2379
Drug: SRT2379
SRT2379 is supplied as hard gelatin capsules containing either 25mg or 250mg free-base equivalent of SRT23790 drug substance as its succinate salt.
Placebo Comparator: Placebo
Single oral administration of placebo
Drug: Placebo
For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.

  Eligibility

Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy, as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination (PE) and laboratory tests carried out within 21 days prior to Day 1. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
  • Male between 18 and 35 years of age, inclusive, at the time of signing the informed consent
  • Capable of giving written informed consent and able to comply with the requirements and restrictions listed in the informed consent form

    - Chemistry panel, including renal and liver function tests, without any clinically relevant abnormality as judged by the Investigator

  • Subjects must agree to use double-barrier birth control or abstinence while participating in the study and for 7 days following the last dose of study drug

Exclusion Criteria:

  • Subject has had a major illness in the past 3 months or any significant chronic medical illness that the Investigator would deem unfavourable for enrolment, including inflammatory diseases
  • Subjects with a history of any type of malignancy with the exception of successfully treated basal cell cancer of the skin
  • Subject has a past or current gastrointestinal disease which may influence drug absorption
  • The subject has a known positive test for hepatitis C antibody, hepatitis B surface antigen or human immunodeficiency virus (HIV) antibody 1 or 2

    • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
    • Subject has a history, within 3 years, of drug abuse (including benzodiazepines, opioids, amphetamine, cocaine, THC, methamphetamine) or a positive drug result at the Screening visit
    • History of alcoholism and/or is drinking more than 3 units of alcohol per day. Alcoholism is defined as an average weekly intake of >21 units for males. One unit is equivalent to 8 g of alcohol: a half-pint (~240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits
    • The subject has received an investigational product within three months of the first dosing day in the current study; Note: any subject who has participated in a prior human endotoxemia study with SRT2379 or SRT2104 would be excluded from participation in this trial.
    • Use of prescription or non-prescription drugs and herbal and dietary supplements within 7 days unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise subject safety
    • Subject has difficulty donating blood or limited accessibility of a vein in left and right arm
  • Subject has donated more than 350 mL of blood in last 3 months
  • Subject uses tobacco products

    • Any clinically relevant abnormality noted on the 12-lead ECG as judged by the Investigator or an average QTcB or QTcF > 450 msec
    • Any other issue that, in the opinion of the Investigator , could be harmful to the subject or compromise interpretation of the data
  • Prior participation in a trial where the subject received intravenous endotoxin (LPS) infusion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01416376

Locations
Netherlands
GSK Investigational Site
Amsterdam, Netherlands, 1105 AZ
Sponsors and Collaborators
Sirtris, a GSK Company
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier: NCT01416376     History of Changes
Other Study ID Numbers: 115830
Study First Received: July 28, 2011
Last Updated: February 16, 2012
Health Authority: Netherlands: Centrale Commissie Mensgebonden Onderzoek

ClinicalTrials.gov processed this record on September 18, 2014